Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Talha Badar*, Ehab Atallah, Rory M. Shallis, Aaron D. Goldberg, Anand Patel, Yasmin Abaza, Jan P. Bewersdorf, Antoine N. Saliba, Guilherme Sacchi De Camargo Correia, Guru Murthy, Adam Duvall, Madelyn Burkart, Maximilian Stahl, Yuanhang Liu, Shira Dinner, Neil Palmisiano, Mark R. Litzow, James M. Foran

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

32 Scopus citations
Original languageEnglish (US)
Pages (from-to)E232-E235
JournalAmerican Journal of Hematology
Volume97
Issue number7
DOIs
StatePublished - Jul 2022

Funding

Talha Badar received Mayo Clinic Cancer Center support grant (P30 CA015083) and in advisory board for Pfizer; Aaron D. Goldberg received research funding from Celularity, ADC Therapeutics, Aprea, AROG, Pfizer, Prelude, and Trillium; received research funding from and served as a consultant for Aptose and Daiichi Sankyo; served as a consultant and member of advisory committees for Astellas, Celgene, and Genentech; received research funding from, served as a consultant for, and was a member of advisory committees for AbbVie; and received honoraria from Dava Oncology; Anand Patel received research funding from Celgene/BMS and Agios/Servier.

ASJC Scopus subject areas

  • Hematology

Cite this